| Name | Title | Contact Details |
|---|
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
Since our first facility opened in 1970, Life Care`s associates have positively impacted the company`s mission of providing exceptional patient care. Life Care owns or manages more than 200 facilities and employs approximately 40,000 individuals who strive daily to make a difference in the lives of those we serve. Our facilities offer multiple levels of patient care and services, which vary by location. We offer post-acute care and inpatient and outpatient therapy in well-equipped, on-site rehabilitation gyms. We believe that as a privately owned company, Life Care Centers of America stands apart from others. We offer a resident-centered corporate culture with more than 45 years of experience, stability and success. Our modern and well-maintained facilities feature strong multidisciplinary teams, specialty programs and opportunities for continuing education.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
University Hospitals, one of the nation`s leading health care systems, focuses on providing compassionate, quality medical care to patients at convenient locations throughout Northeast Ohio.
Hartford HealthCare is Connecticut`s most comprehensive healthcare network. With 33,000 employees and total operating revenue of $4.3 billion, Hartford HealthCare has cultivated a strong, unified culture of accountability and innovation. Its care-delivery system, serving 185 towns and cities at more than 400 locations, includes two tertiary-level teaching hospitals, an acute-care community teaching hospital, an acute-care hospital and trauma center, three community hospitals, the state`s most extensive behavioral health network, a large multispecialty physician group, a clinical care organization, a regional home care system, an array of senior care services, and a large physical therapy and rehabilitation network. Hartford HealthCare`s unique, systemwide Institute Model offers a single, high standard of care in crucial specialties at hospital and ambulatory sites across Connecticut. The institutes include: Cancer, Heart and Vascular, Neuroscience, Orthopedics and Urology.